Stay updated with breaking news from Sci Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For Trade and Medical Media Only Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor
/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of...
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE
- Vurolenatide's half-life is consistent with twice-monthly dosing -- Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end -RALEIGH, NC / ACCESSWIRE / October
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying